Panmure Gordon Analyst Dr Mike Mitchell said this morning on Collagen Solutions: “Prelim results have delivered a performance in-line with our expectations. The company reports revenue and other income of £1.04m (PGe £1.0m, 2014: £0.02m) and adjusted EBITDA loss of £0.69m (before £155k separately identifiable items relating to acquisition/integration of Southern Lights), or reported EBITDA loss of £0.85m vs PGe loss £0.93m. At the pre-tax level, Collagen reports an adjusted loss of £0.95m vs PGe loss £1.21m. Net cash balances at the year-end were £3.4m (2014: £1.49m), ahead of our £2.8m estimate. This is an early-stage business but one with long-term growth potential.”
Collagen Solutions Targeting long-term sustainable growth
19th December 2017
Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced to accelerate the rate
